Financial Impact Analysis

Financial or Budget Impact Analysis is a mandatory part of the CDR (Common Drug Review) and provincial drug plan submissions. A high quality assessment that anticipates questions and challenges can mean the difference between quick market access and costly delays and rejections.

With over 14 years of experience in BIA preparation and using each drug plan's own drug utilisation data, Brogan Inc. is well positioned to help with drug plan specific analyses of the expected financial impact of the company's new drug on the respective drug plan budgets.

Employing drug plan specific data helps minimize uncertainty for decision-makers' part with respect to the applicability of the data used in the analysis.

For new drugs with no provincial plan history, we employ Brogan Inc.'s wealth of prescription (patient) level data from private drug plans. This actual utilization history can provide strong justification for key assumptions that will be necessary for the new drug.

For more infomration on BIA preparation and our BIA training seminars, please contact our Health Economics department at 613.599.0711.